Spectrum of addictions in Parkinson's disease: From dopamine dysregulation syndrome to impulse control disorders

Journal of Neurology

Volumn 257, Issue SUPPL. 2, 2010, Pages

  Ceravolo, Roberto ^a   Frosini, Daniela ^a   Rossi, Carlo ^a   Bonuccelli, Ubaldo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Behavioral addiction; Dopamine dysregulation syndrome; Impulse control disorders; Parkinson's disease

Indexed keywords

ANTIDEPRESSANT AGENT; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NALMEFENE; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; ROPINIROLE; SELEGILINE; ANTIPARKINSON AGENT;

ACUTE PSYCHOSIS; ADDICTION; BEHAVIOR DISORDER; BIPOLAR DISORDER; COGNITIVE THERAPY; COMPULSION; CONFERENCE PAPER; CONTINUOUS INFUSION; DEPRESSION; DOPAMINE DYSREGULATION SYNDROME; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; FAMILY HISTORY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC PREDISPOSITION; GENETIC RISK; GROUPS BY AGE; HUMAN; HYPERSEXUALITY; HYPOMANIA; IMPULSE CONTROL DISORDER; INTERMITTENT EXPLOSIVE DISORDER; KLEPTOMANIA; LOW DRUG DOSE; MOOD DISORDER; NEUROBIOLOGY; NEUROIMAGING; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PATIENT COUNSELING; PERSONALITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOTHERAPY; PYROMANIA; RECOMMENDED DRUG DOSE; REWARD; RISK FACTOR; SEX DIFFERENCE; SUBSTANCE ABUSE; TRICHOTILLOMANIA; METABOLISM; REVIEW; SYNDROME;

ANTIPARKINSON AGENTS; DOPAMINE AGENTS; HUMANS; SUBSTANCE-RELATED DISORDERS; SYNDROME;

EID: 79959858259     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5715-0     Document Type: Conference Paper

References (60)

1. Jaffe JH (2001) Goodman and Gilman's the pharmacological basis of therapeutics. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) 8th edn. Pergamon, New York, pp 522-573
2. World Health Organization (1990) International statistical classification of diseases and related health problems - 10th revision, World Health Organization, Geneva
3. Spanagel R, Heilig M (2005) Addiction and its brain science. Addiction 100(12):1813-1822 (Pubitemid 41775206)
4. Heidbreder CA, Gardner EL, Xi ZX, Thanos PK, Mugnaini M, Hagan JJ et al (2005) The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Rev 49(1):77-105 (Pubitemid 40800164)
5. Bressan RA, Crippa JA (2005) The role of dopamine in reward and pleasure behaviour - review of data from preclinical research. Acta Psychiatr Scand Suppl 427:14-21 (Pubitemid 40780195)
6. Koepp MJ, Gunn RN, Lawrence AD, Cunningham VJ, Dagher A, Jones T et al (1998) Evidence for striatal dopamine release during a video game. Nature 393:266-268 (Pubitemid 28261725)
7. Koob GF, Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278(5335):52-58 (Pubitemid 27446270)
8. Robinson TE, Berridge KC (2000) The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95(Suppl. 2):S91-S117 (Pubitemid 30650375)
9. Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24(2):97-129
10. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ (2000) Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68:423-428 (Pubitemid 30248740)
11. Evans AH, Katzenschlager R, Paviour D, O'Sullivan JD, Appel S, Lawrence AD, Lees AJ (2004) Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19:397-405 (Pubitemid 38559642)
12. Miyasaki JM, Al Hassan K, Lang AE, Voon V (2007) Punding prevalence in Parkinson's disease. Mov Disord 22(8):1179-1181 (Pubitemid 47067232)
13. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington
14. Weintraub D (2008) Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol 64(Suppl 2):S93-S100
15. Holden C (2001) 'Behavioral' addictions: do they exist? Science 294:980-982
16. Tamminga CA, Nestler EJ (2006) Pathological gambling: focusing on the addiction, not the activity. Am J Psychiatry 163:303-312
17. Brewer JA, Potenza MN (2008) The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol 75:63-75 (Pubitemid 350235392)
18. Hollander E, Allen A (2006) Is compulsive buying a real disorder, and is it really compulsive? Am J Psychiatry 163:1670-1672 (Pubitemid 44522468)
19. Pezzella FR, Colosimo C, Vanacore N, Di Rezze S, Chianese M, Fabbrini G et al (2005) Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 20(1):77-81 (Pubitemid 40277510)
20. Giladi N, Weitzman N, Schreiber S, Shabtai H, Peretz C (2007) New-onset heightened interest or drive for gambling, shopping, eating, or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 21:501-506 (Pubitemid 47106924)
21. Driver-Dunckley E, Samanta J, Stacy M (2003) Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 61:422-423 (Pubitemid 36975988)
22. Lu C, Bharmal A, Suchowersky O (2006) Gambling and Parkinson's disease. Arch Neurol 63:298
23. Grosset KA, Macphee G, Pal G, Stewart D, Watt A, Davie J, Grosset DG (2006) Problematic gambling on dopamine agonists: not such a rarity. Mov Disord 21:2206-2208 (Pubitemid 46140438)
24. Voon V, Hassan K, Zurowski M, Duff-Canning S, de Souza M, Fox S, Lang AE, Miyasaki J (2006) Prospective prevalence of pathological gambling and medication association in Parkinson disease. Neurology 66:1750-1752 (Pubitemid 43964638)
25. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, Moberg PJ, Stern MB (2006) Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63:969-973 (Pubitemid 44036299)
26. Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S, Lang AE, Miyasaki J (2006) Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67:1254-1257 (Pubitemid 44563838)
27. Isaias IU, Siri C, Cilia R, De Gaspari D, Pezzoli G, Antonini A (2008) The relationship between impulsivity and impulse control disorders in Parkinson's disease. Mov Disord 23:411-415
28. Christenson GA, Faber RJ, deZwaan M (1994) Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry 55:5-11 (Pubitemid 24051910)
29. Crockford D, Quickfall J, Currie S, Furtado S, Suchowersky O, El-Guebaly N (2008) Prevalence of problem and pathological gambling in Parkinson's disease. J Gambl Stud 24(4):411-422
30. Avanzi M, Baratti M, Cabrini S, Bonfà F, Brighetti G, Uber E (2006) Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 21:2068-2072 (Pubitemid 46140413)
31. Ceravolo R, Frosini D, Rossi C, Nicoletti V, Berti C, Unti E, et al. (2009) Prevalence of Impulse control disorders in Parkinson's disease. Neurol Sci 30(Suppl):S456
32. Vogel HP, Shiffer R (1983) Hypersexuality: a complication of dopaminergic therapy in Parkinson's disease. Pharmacopsychiatria 16:107-110 (Pubitemid 13002434)
33. Harvey NS (1988) Serial cognitive profiles in levodopa-induced hypersexuality. Br J Psychiatry 153:833-836
34. Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B (1989) Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12:375-383 (Pubitemid 20008761)
35. O'Sullivan JD, Hughes AJ (1998) Apomorphine-induced penile erections in Parkinson's disease. Mov Disord 13:536-539 (Pubitemid 28221510)
36. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE (2005) Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 11:381-386 (Pubitemid 41317806)
37. Lawrence AD, Evans AH, Lees AJ (2003) Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2(10):595-604 (Pubitemid 37162568)
38. Bearn J, Evans A, Kelleher M, Turner K, Lees A (2004) Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. Drug Alcohol Depend 76(3):305-310 (Pubitemid 39556360)
39. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A (2007) Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. Mov Disord 22:1757-1763 (Pubitemid 47597599)
40. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ (2005) Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 65:1570-1574 (Pubitemid 41689470)
41. Singh A, Kandimala G, Dewey RB Jr, O'Suilleabhain P (2007) Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J Clin Neurosci 14:1178-1181 (Pubitemid 350102789)
42. Voon V, Thomsen T, Miyasaki JM, de Souza M, Shafro A, Fox SH, Duff-Canning S, Lang AE, Zurowski M (2007) Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 64:212-216
43. Pontone G, Williams JR, Bassett SS, Marsh L (2006) Clinical features associated with impulse control disorders in Parkinson disease. Neurology 67:1258-1261 (Pubitemid 44563839)
44. Santangelo G, Vitale C, Trojano L, Verde F, Grossi D, Barone P (2009) Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. Mov Disord 24(6):899-905
45. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE (2005) Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62:1377-1381 (Pubitemid 41352054)
46. Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, Krahn L, Adler CH (2007) Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 30(5):249-255 (Pubitemid 47511504)
47. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE (1995) Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 5(3):121-141
48. Comings DE, Gonzalez N, Wu S, Gade R, Muhleman D, Saucier G, Johnson P, Verde R, Rosenthal RJ, Lesieur HR, Rugle LJ, Miller WB, MacMurray JP (1999) Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet 88(4):358-368 (Pubitemid 29372249)
49. Pérez de Castro I, Ibáñez A, Torres P, Sáiz-Ruiz J, Fernández-Piqueras J (1997) Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics 7(5):345-348
50. Lee JY, Lee EK, Park SS, Lim JY, Kim HJ, Kim JS, Jeon BS (2009) Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov Disord 24:1803-1810
51. Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M, Brooks DJ, Lees AJ, Piccini P (2006) Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59(5):852-858 (Pubitemid 43673163)
52. Reuter J, Raedler T, Rose M, Hand I, Gläscher J, Büchel C (2005) Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 8(2):147-148 (Pubitemid 40194043)
53. Cilia R, Siri C, Marotta G, Isaias IU, De Gaspari D, Canesi M, Pezzoli G, Antonini A (2008) Functional abnormalities underlying pathological gambling in Parkinson disease. Arch Neurol 65(12):1604-1611
54. Steeves TD, Miyasaki J, Zurowski M, Lang AE, Pellecchia G, Van Eimeren T, Rusjan P, Houle S, Strafella AP (2009) Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 132:1376-1385
55. Frosini D, Pesaresi I, Rossi C, De Feo P, Cosottini M, Bonuccelli U, Ceravolo R (2009) Parkinson's disease and pathological gambling: results from a fMRI study invesigating cue-induced brain activity. Parkinsonism Rel Dis 15(2):S52
56. Mamikonyan E, Siderowf AD, Duda JE, Potenza MN, Horn S, Stern MB, Weintraub D (2008) Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 23:75-80 (Pubitemid 351281221)
57. Jimenez-Jimenez FJ, Sayed Y, Garcia-Soldevilla MA, Barcenilla B (2002) Possible zoophilia associated with dopaminergic therapy in Parkinson disease. Ann Pharmacother 36:1178-1179 (Pubitemid 34755795)
58. Gschwandtner U, Aston J, Renaud S, Fuhr P (2001) Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 24:170-172 (Pubitemid 32549993)
59. Grant JE, Potenza MN (2004) Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry 16:27-34 (Pubitemid 40029201)
60. Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, Kallio A (2006) Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 163:303-312 (Pubitemid 44480852)